Back to Journals » Vascular Health and Risk Management » Volume 10

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice

Authors Nallur Shivu G, Ossei-Gerning N

Received 19 December 2013

Accepted for publication 8 February 2014

Published 12 May 2014 Volume 2014:10 Pages 291—302

DOI https://doi.org/10.2147/VHRM.S59420

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Ganesh Nallur Shivu,1 Nick Ossei-Gerning2

1Department of Cardiology, King's Mill Hospital, Sutton-in-Ashfield, Nottinghamshire, UK; 2Department of Cardiology, University Hospital of Wales, Cardiff, UK

Abstract: Despite significant advances in the management of acute coronary syndrome (ACS) and long-term antiplatelet therapy after an ACS event, patients continue to be at risk of further cardiovascular events. There is evidence that recurrent events are at least partly attributed to the persistent activation of the coagulation system after ACS. Various anticoagulants, including vitamin K antagonists (VKAs) and non-VKA oral anticoagulants, have been evaluated in patients post-ACS, in combination with antiplatelet therapy. The desired outcome would be a further reduction of recurrent cardiovascular events with low or acceptable levels of bleeding complications. Here, we provide an overview of the current clinical trial data of non-VKA oral anticoagulants, focusing on rivaroxaban in particular, for secondary prevention in patients with a recent ACS event.

Keywords: acute coronary syndrome, anticoagulants, antiplatelet therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]